Sign In
Buy ATAI
$4.53
-0.280 (-5.82%)
At Close: Jun 03, 2026
- A single dose of BPL-003 demonstrated a rapid and durable antidepressant effect in TRD patients, with 45% of patients in clinical remission at week 12
atai Life Sciences doses first patient in Phase 1b study of its optimized oral DMT formulation
08:59am, Monday, 04'th Mar 2024
atai Life Sciences (NASDAQ:ATAI, ETR:9VC) announced that it has dosed the first healthy participant in a Phase 1b trial evaluating its oral transmucosal film formulation of DMT VLS-01, which is being
atai Life Sciences Announces First Participant Dosed in Phase 1b Trial of VLS-01
08:00am, Monday, 04'th Mar 2024
NEW YORK and BERLIN, March 04, 2024 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company aiming to transform the treatment of
atai Life Sciences to Participate in the Upcoming TD Cowen 44th Annual Health Care Conference
05:00pm, Wednesday, 28'th Feb 2024
NEW YORK and BERLIN, Feb. 28, 2024 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health di
Therapy's New Frontier: 3 Psychedelic Stocks for the Mental Health Revolution
01:56pm, Tuesday, 09'th Jan 2024
Though psychedelic therapies and related psychedelic stocks have fallen out of favor recently, there's still tremendous research and insight happening beneath the surface. Even Elon Musk uses ketamine
3 Big New Catalysts for Psychedelics Stocks in 2024
11:47am, Monday, 08'th Jan 2024
Psychedelics stocks could be buoyed by a few positive events soon. The government is now funding the study of certain psychedelics.
atai Life Sciences expands its pipeline with $50M investment in Beckley Psytech
02:46am, Friday, 05'th Jan 2024
Psychedelic drug development firm atai Life Sciences (NASDAQ:ATAI) is investing $50 million in UK-based Beckley Psytech as part of a collaboration that gives the company exposure to a Phase 2 psychede
Atai Life Sciences reports positive data from early-stage R-MDMA study
10:32am, Tuesday, 02'nd Jan 2024
atai Life Sciences (NASDAQ:ATAI) shares moved more than 13% higher Tuesday after the company reported positive findings from its early-stage study of EMP-01, Atai's R-isomer of MDMA. The company said
Why You Should Bet on 5 Top-Ranked Stocks With Rising P/E
08:16am, Thursday, 28'th Dec 2023
Tap four stocks with increasing P/E ratios to try out an out-of-the-box approach. These stocks include DouYu International (DOYU), Regis (RGS), 2seventy bio Inc. (TSVT), atai Life Sciences (ATAI) and
5 Biotech stocks tapping into unmet mental health treatment needs
09:01am, Wednesday, 20'th Dec 2023
Anyone who has dealt with a mental illness or has a loved one who struggles with a mental illness knows how devastating these diseases are. However, a growing number of biotechnology companies are giv
atai Life Sciences N.V. (ATAI) Upgraded to Buy: Here's Why
01:32pm, Friday, 17'th Nov 2023
atai Life Sciences N.V. (ATAI) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Psychedelics CEOs heartened by MDMA for PTSD study results as stocks maintain momentum
01:22pm, Friday, 15'th Sep 2023
The success of a Phase 3 trial of MDMA for post-traumatic stress disorder (PTSD) which has put the therapy on track for U.S. Food and Drug Administration (FDA) approval in 2024 has been celebrated by
atai Life Sciences to Participate in the 2023 Cantor Fitzgerald Global Healthcare Conference
08:02am, Thursday, 14'th Sep 2023
NEW YORK and BERLIN, Sept. 14, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health d
atai Life Sciences to Participate in Upcoming September Investor Conferences
04:01pm, Wednesday, 06'th Sep 2023
NEW YORK and BERLIN, Sept. 06, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health d
atai Life Sciences N.V. (ATAI) Loses -15.43% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
11:18am, Wednesday, 06'th Sep 2023
atai Life Sciences N.V. (ATAI) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it.
